Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.

Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S211-5.

PMID:
15838282
2.

Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.

Firooznia F, Gude C, Chan K, Tan J, Fink CA, Savage P, Beil ME, Bruseo CW, Trapani AJ, Jeng AY.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3059-62.

PMID:
12372501
3.

Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.

Trapani AJ, Beil ME, Bruseo CW, Fink CA, Hoyer D, Savage P, Jeng AY.

Clin Sci (Lond). 2002 Aug;103 Suppl 48:102S-106S.

PMID:
12193065
4.

CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.

Jeng AY, Savage P, Beil ME, Bruseo CW, Hoyer D, Fink CA, Trapani AJ.

Clin Sci (Lond). 2002 Aug;103 Suppl 48:98S-101S.

PMID:
12193064
5.

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.

Firooznia F, Gude C, Chan K, Fink CA, Qiao Y, Satoh Y, Marcopoulos N, Savage P, Beil ME, Bruseo CW, Trapani AJ, Jeng AY.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):375-8.

PMID:
11212114
6.

Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.

Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S40-3.

PMID:
11078331
7.

Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.

Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S36-9.

PMID:
11078330
8.

Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.

Fink CA, Moskal M, Firooznia F, Hoyer D, Symonsbergen D, Wei D, Qiao Y, Savage P, Beil ME, Trapani AJ, Jeng AY.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):2037-9.

PMID:
10987444
9.

CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.

Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY.

Life Sci. 2000;67(9):1025-33.

PMID:
10954036
10.

Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.

De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, Fitt J, Hoyer D, Simonsbergen D, Moliterni J, Marcopoulos N, Savage P, Chou M, Trapani AJ, Jeng AY.

J Med Chem. 2000 Feb 10;43(3):488-504.

PMID:
10669576
11.

Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.

Wallace EM, Moliterni JA, Moskal MA, Neubert AD, Marcopulos N, Stamford LB, Trapani AJ, Savage P, Chou M, Jeng AY.

J Med Chem. 1998 Apr 23;41(9):1513-23.

PMID:
9554884
12.

Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.

Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S71-3.

PMID:
9595404
13.

Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.

Chatelain RE, Ghai RD, Trapani AJ, Odorico LM, Dardik BN, De Lombaert S, Lappe RW, Fink CA.

J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.

PMID:
9495857
14.

Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

Fink CA, Carlson JE, McTaggart PA, Qiao Y, Webb R, Chatelain R, Jeng AY, Trapani AJ.

J Med Chem. 1996 Aug 2;39(16):3158-68.

PMID:
8759637
15.

New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.

Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai RD, Trapani AJ.

J Med Chem. 1995 Dec 22;38(26):5023-30.

PMID:
8544178
16.

A rapid indirect method to determine the plasma concentrations of neutral endopeptidase inhibitors.

Ghai RD, De Lombaert S, Ksander GM, Berry C, Sakane Y, Trapani AJ.

Res Commun Mol Pathol Pharmacol. 1995 Feb;87(2):211-20.

PMID:
7749658
17.
18.

Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.

De Lombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL.

Biochem Biophys Res Commun. 1994 Oct 14;204(1):407-12.

PMID:
7945387
19.

Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.

Trapani AJ, Beil ME, Coté DT, de Lombaert S, Erion MD, Gerlock TE, Ghai RD, Hopkins MF, Peppard JV, Webb RL, et al.

J Cardiovasc Pharmacol. 1994 Mar;23(3):358-64.

PMID:
7515977
20.

N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.

De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ.

J Med Chem. 1994 Feb 18;37(4):498-511.

PMID:
8120868
21.

The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11.

Trapani AJ, De Lombaert S, Erion MD, Ghai RD, Peppard JV, Lappe RW, Worcel M.

J Hypertens Suppl. 1993 Dec;11(5):S220-1. No abstract available.

PMID:
8158354
22.

Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.

Trapani AJ, Balwierczak JL, Lappe RW, Stanton JL, Graybill SC, Hopkins MF, Savage P, Sperbeck DM, Jeng AY.

Biochem Mol Biol Int. 1993 Dec;31(5):861-7.

PMID:
8136704
23.

Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.

Stanton JL, Sperbeck DM, Trapani AJ, Cote D, Sakane Y, Berry CJ, Ghai RD.

J Med Chem. 1993 Nov 26;36(24):3829-33.

PMID:
8254612
24.

Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.

MacPherson LJ, Bayburt EK, Capparelli MP, Bohacek RS, Clarke FH, Ghai RD, Sakane Y, Berry CJ, Peppard JV, Trapani AJ.

J Med Chem. 1993 Nov 26;36(24):3821-8.

PMID:
8254611
25.

Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.

Trapani AJ, Smits GJ, McGraw DE, McMahon EG, Blaine EH.

J Pharmacol Exp Ther. 1991 Jul 1;258(1):269-74.

PMID:
1649294
26.

A comparison of the hemodynamic effects of endothelin-1 and sarafotoxin S6b in conscious rats.

Han SP, Trapani AJ, Fok KF, Westfall TC, Knuepfer MM.

J Pharmacol Exp Ther. 1991 Jan;256(1):183-8.

PMID:
1988658
27.

Atriopeptin regulation and renal function in conscious spontaneously hypertensive rats.

Koepke JP, Tyler LD, Mehta PP, Olins GM, Trapani AJ, Hartupee DA, Bovy PR, Spear KL, Blaine EH.

Am J Hypertens. 1990 Aug;3(8 Pt 1):622-7.

PMID:
2171564
28.

Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters.

Smits GJ, McGraw DE, Trapani AJ, Blaine EB.

J Pharmacol Exp Ther. 1990 Jul;254(1):176-9.

PMID:
2142219
29.

Central and peripheral actions of a nonpeptidic angiotensin II receptor antagonist.

Koepke JP, Bovy PR, McMahon EG, Olins GM, Reitz DB, Salles KS, Schuh JR, Trapani AJ, Blaine EH.

Hypertension. 1990 Jun;15(6 Pt 2):841-7.

PMID:
2190928
30.

Structure-activity relationships for the carboxy-terminus truncated analogues of angiotension II, a new class of angiotensin II antagonists.

Bovy PR, O'Neal JM, Olins GM, Patton DR, McMahon EG, Palomo M, Koepke JP, Salles KS, Trapani AJ, Smits GJ, et al.

J Med Chem. 1990 May;33(5):1477-82.

PMID:
2329570
31.

Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects.

Smits GJ, McGraw DE, Trapani AJ.

Am J Physiol. 1990 May;258(5 Pt 2):F1417-24.

PMID:
2140018
32.

Endothelin and sarafotoxin S6b have similar vasoconstrictor effects and postsynaptically mediated mechanisms.

Han SP, Knuepfer MM, Trapani AJ, Fok KF, Westfall TC.

Eur J Pharmacol. 1990 Feb 20;177(1-2):29-34.

PMID:
2187702
33.

Cardiac and vascular actions of sarafotoxin S6b and endothelin-1.

Han SP, Knuepfer MM, Trapani AJ, Fok KF, Westfall TC.

Life Sci. 1990;46(11):767-75.

PMID:
2181224
34.

Regional hemodynamic and baroreflex effects of endothelin in rats.

Knuepfer MM, Han SP, Trapani AJ, Fok KF, Westfall TC.

Am J Physiol. 1989 Sep;257(3 Pt 2):H918-26.

PMID:
2675635
35.

Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide.

Trapani AJ, Smits GJ, McGraw DE, Spear KL, Koepke JP, Olins GM, Blaine EH.

J Cardiovasc Pharmacol. 1989 Sep;14(3):419-24.

PMID:
2476621
36.

Baroreceptor denervation profoundly enhances cardiovascular responses to central angiotensin II.

Barron KW, Trapani AJ, Gordon FJ, Brody MJ.

Am J Physiol. 1989 Jul;257(1 Pt 2):H314-23.

PMID:
2568757
37.

In vitro and in vivo activity of chymotrypsin-activated big endothelin (porcine 1-40).

McMahon EG, Fok KF, Moore WM, Smith CE, Siegel NR, Trapani AJ.

Biochem Biophys Res Commun. 1989 Jun 15;161(2):406-13.

PMID:
2660786
38.

Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats.

Koepke JP, Tyler LD, Trapani AJ, Bovy PR, Spear KL, Olins GM, Blaine EH.

J Pharmacol Exp Ther. 1989 Apr;249(1):172-6.

PMID:
2565386
39.

A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.

Bovy PR, Trapani AJ, McMahon EG, Palomo M.

J Med Chem. 1989 Mar;32(3):520-2. No abstract available.

PMID:
2918497
40.

Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo.

Olins GM, Krieter PA, Trapani AJ, Spear KL, Bovy PR.

Mol Cell Endocrinol. 1989 Feb;61(2):201-8.

PMID:
2521834
41.

Role of renal nerves in the potentiation of atriopeptin-induced natriuresis by vasopressin.

Hartupee DA, Trapani AJ, Koepke JP, Blaine EH.

Circ Res. 1989 Feb;64(2):370-5.

PMID:
2521463
42.

Effects of endothelin on regional hemodynamics in conscious rats.

Han SP, Trapani AJ, Fok KF, Westfall TC, Knuepfer MM.

Eur J Pharmacol. 1989 Jan 17;159(3):303-5.

PMID:
2646136
43.

Metabolism of atrial natriuretic peptide. Extraction by organs in the rat.

Krieter PA, Trapani AJ.

Drug Metab Dispos. 1989 Jan-Feb;17(1):14-9.

PMID:
2566463
44.

Neurohumoral interactions in conscious dehydrated rabbit.

Trapani AJ, Undesser KP, Keeton TK, Bishop VS.

Am J Physiol. 1988 Feb;254(2 Pt 2):R338-47.

PMID:
3278629
45.

Analysis of hemodynamic variability after sinoaortic denervation in the conscious rat.

Trapani AJ, Barron KW, Brody MJ.

Am J Physiol. 1986 Dec;251(6 Pt 2):R1163-9.

PMID:
3789198
46.
47.

Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine.

Bonham AC, Trapani AJ, Portis LR, Brody MJ.

J Hypertens Suppl. 1984 Dec;2(3):S543-6.

PMID:
6599714
48.

Comparative central and peripheral antihypertensive mechanisms of urapidil and prazosin.

Brody MJ, Webb RL, Mangiapane ML, Porter JP, Bonham AC, Trapani AJ.

Am J Med. 1984 Oct 5;77(4A):74-80.

PMID:
6091451
49.

Are increases in cyclic GMP levels responsible for the effects of acetylcholine on the transmembrane action potential of cat atrium?

Diamond J, Ten Eick RE, Trapani AJ.

Proc West Pharmacol Soc. 1984;27:27-30. No abstract available.

PMID:
6093131
50.

Supplemental Content

Loading ...
Support Center